Augmedix, a company that say it turns natural clinician-patient conversation into medical documentation, announced on Wednesday, that Joe Marks, executive director of the Center for Machine Learning & Health at Carnegie Mellon University has been named as the company's new director.
Marks brings to the company extensive experience across such disciplines as artificial intelligence and human-in-the-loop automation. He has run the research labs at both Mitsubishi Electric and The Walt Disney Company. He has worked on DARPA-sponsored research projects for the US government, co-founded two start-ups, and has served as an advisor and consultant to the American Medical Association, all in addition to his current work at Carnegie Mellon. At Augmedix, Marks' official title will be independent director.
Manny Krakaris, chief executive officer at Augmedix, said, 'Augmedix is aggressively pursuing automation innovation in medical note documentation, data aggregation, and analysis. Joe Marks has an established record of pushing technical boundaries of artificial intelligence and machine learning, particularly within health care. We're delighted to have someone of Joe's stature join our team and apply his unique expertise to enhance our efforts in this area.'
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA